Literature DB >> 32616434

Risk predictors in a Spanish cohort with cardiac laminopathies. The REDLAMINA registry.

Roberto Barriales-Villa1, Juan P Ochoa2, José M Larrañaga-Moreira3, Joel Salazar-Mendiguchía4, Carles Díez-López5, María Alejandra Restrepo-Córdoba6, Jorge Álvarez-Rubio7, Ainhoa Robles-Mezcua8, María C Olmo-Conesa9, Elisa Nicolás-Rocamora9, Jorge Sanz10, Eduardo Villacorta11, María Gallego-Delgado11, Raquel Yotti12, María Ángeles Espinosa12, Ana Manovel13, Luis M Rincón-Díaz14, Juan Jiménez-Jaimez15, Francisco J Bermúdez-Jiménez15, M Teresa Basurte-Elorz16, Vicente Climent-Payá17, María I García-Álvarez17, José Fernando Rodríguez-Palomares18, Javier Limeres-Freire18, Ainhoa Pérez-Guerrero19, Eva M Cantero-Pérez20, María L Peña-Peña20, Julián Palomino-Doza21, María G Crespo-Leiro22, José M García-Pinilla8, Esther Zorio23, Tomás Ripoll-Vera7, Pablo García-Pavía24, Martín Ortiz-Genga2, Lorenzo Monserrat25.   

Abstract

INTRODUCTION AND
OBJECTIVES: According to sudden cardiac death guidelines, an implantable cardioverter-defibrillator (ICD) should be considered in patients with LMNA-related dilated cardiomyopathy (DCM) and ≥ 2 risk factors: male sex, left ventricular ejection fraction (LVEF) <45%, nonsustained ventricular tachycardia (NSVT), and nonmissense genetic variants. In this study we aimed to describe the clinical characteristics of carriers of LMNA genetic variants among individuals from a Spanish cardiac-laminopathies cohort (REDLAMINA registry) and to assess previously reported risk criteria.
METHODS: The relationship between risk factors and cardiovascular events was evaluated in a cohort of 140 carriers (age ≥ 16 years) of pathogenic LMNA variants (54 probands, 86 relatives). We considered: a) major arrhythmic events (MAE) if there was appropriate ICD discharge or sudden cardiac death; b) heart failure death if there was heart transplant or death due to heart failure.
RESULTS: We identified 11 novel and 21 previously reported LMNA-related DCM variants. LVEF <45% (P=.001) and NSVT (P <.001) were related to MAE, but not sex or type of genetic variant. The only factor independently related to heart failure death was LVEF <45% (P <.001).
CONCLUSIONS: In the REDLAMINA registry cohort, the only predictors independently associated with MAE were NSVT and LVEF <45%. Therefore, female carriers of missense variants with either NSVT or LVEF <45% should not be considered a low-risk group. It is important to individualize risk stratification in carriers of LMNA missense variants, because not all have the same prognosis.
Copyright © 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Dilated cardiomyopathy; Genetics; Genética; LMN; LMNA; Miocardiopatía dilatada; Missense; Sex; Sexo

Mesh:

Year:  2020        PMID: 32616434     DOI: 10.1016/j.rec.2020.03.026

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  2 in total

Review 1.  Clinical Profile, Arrhythmias, and Adverse Cardiac Outcomes in Emery-Dreifuss Muscular Dystrophies: A Systematic Review of the Literature.

Authors:  Anna Chiara Valenti; Alessandro Albini; Jacopo Francesco Imberti; Marco Vitolo; Niccolò Bonini; Giovanna Lattanzi; Renate B Schnabel; Giuseppe Boriani
Journal:  Biology (Basel)       Date:  2022-03-30

2.  Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy.

Authors:  Jesús G Mirelis; Luis Escobar-Lopez; Juan Pablo Ochoa; María Ángeles Espinosa; Eduardo Villacorta; Marina Navarro; Guillem Casas; Nerea Mora-Ayestarán; Roberto Barriales-Villa; María Victoria Mogollón-Jiménez; José M García-Pinilla; Pablo E García-Granja; Vicente Climent; Julian Palomino-Doza; Ana García-Álvarez; María Álvarez-Barredo; Eva Cabrera-Borrego; Tomás Ripoll-Vera; María Luisa Peña-Peña; Elena Rodríguez-González; María Gallego-Delgado; Josefa Gonzalez-Carrillo; Ana Fernández-Ávila; José F Rodríguez-Palomares; Ramón Brugada; Antoni Bayes-Genis; Fernando Dominguez; Pablo García-Pavía
Journal:  Eur J Heart Fail       Date:  2022-05-22       Impact factor: 17.349

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.